PMID- 32295542
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20201218
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 15
TI  - Both comorbidity and worse performance status are associated with poorer overall 
      survival after external beam radiotherapy for prostate cancer.
PG  - 324
LID - 10.1186/s12885-020-06812-6 [doi]
LID - 324
AB  - BACKGROUND: In this retrospective study, we evaluated the biochemical recurrence 
      rate, metastatic disease progression, and prostate cancer-specific and overall 
      survival in patients curatively treated with external beam radiotherapy (EBRT) 
      for early prostate cancer (PC). We also examined the prognostic effect of 
      comorbidity by Charlson Comorbidity Index (CCI) and overall performance status by 
      Eastern Clinical Oncology Group (ECOG) score. METHODS: A total of 665 men treated 
      between 2008 and 2013 were enrolled from Tampere University Hospital, Finland. 
      Prostate-specific antigen (PSA) tests and hospital records were used to determine 
      the 5-year survival for each aforementioned endpoint using a Kaplan-Meyer 
      estimate. To analyze the impact of the selected prognostic factor, we used a Cox 
      regression model to calculate the corresponding hazard ratio (HR) and 95% 
      confidence interval (CI). RESULTS: With a median follow-up-time of 7.12 years, 
      the 5-year overall survival (OS) after EBRT was 88.9% [86.5 -91.3%], prostate 
      cancer-specific survival (PCSS) was 97.9% [96.7 -99.1%], metastasis-free survival 
      (MFS) 94.8% [93.0 -96.6%] and biochemical recurrence-free survival (BRFS) 88.7% 
      [86.2 -91.2%]. Both CCI (HR = 1.38, [1.25-1.51]) and ECOG score (HR = 1.63, 
      [1.29-2.05]) declined OS, as well as Gleason score and T score (P <  0.05). 
      Gleason score and T grade also associated to worse PCSS, MFS and BRFS. 
      CONCLUSIONS: CCI and ECOG score are useful tools in evaluating the overall life 
      expectancy of the patient after EBRT for PC. T-stage and Gleason score remain 
      still the major prognostic factors.
FAU - Lehtonen, Miikka
AU  - Lehtonen M
AD  - Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. 
      miikka.m.lehtonen@tuni.fi.
FAU - Heiskanen, Lauri
AU  - Heiskanen L
AD  - Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
FAU - Reinikainen, Petri
AU  - Reinikainen P
AD  - Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
AD  - Department of Oncology, Tampere University Hospital, Tampere, Finland.
FAU - Kellokumpu-Lehtinen, Pirkko-Liisa
AU  - Kellokumpu-Lehtinen PL
AD  - Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
AD  - Department of Oncology, Tampere University Hospital, Tampere, Finland.
LA  - eng
GR  - 9U020/Tays/
PT  - Journal Article
DEP - 20200415
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Comorbidity
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Prostate-Specific Antigen/*metabolism
MH  - Prostatic Neoplasms/metabolism/*pathology/*radiotherapy
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7160996
COIS- The authors declare no competing interests.
EDAT- 2020/04/17 06:00
MHDA- 2020/12/19 06:00
PMCR- 2020/04/15
CRDT- 2020/04/17 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/04/15 00:00 [pmc-release]
AID - 10.1186/s12885-020-06812-6 [pii]
AID - 6812 [pii]
AID - 10.1186/s12885-020-06812-6 [doi]
PST - epublish
SO  - BMC Cancer. 2020 Apr 15;20(1):324. doi: 10.1186/s12885-020-06812-6.